HAIXI PHARMA (02637.HK): Controlling Shareholders Pledge 12-Month Lock-up

NewTimeSpace News: Fujian Haixi Pharmaceuticals Co., Ltd. (stock code: 02637) announced on a voluntary basis that its founder and controlling shareholder Dr. Kang Xinshan and Ms. Feng Yan, who are spouses and parties acting in concert, have given a voluntary lock-up undertaking not to sell, transfer or otherwise dispose of any shares directly held by them during the 12-month period from the date of the announcement to 5 November 2027 (inclusive). The undertaking is additional to the lock-up obligations under applicable laws and the Listing Rules.

As at the date of the announcement, Dr. Kang directly holds 12,759,114 shares (about 16.21% of the total issued share capital) and Ms. Feng directly holds 9,918,426 shares (about 12.60%), totalling 22,677,540 shares (about 28.81%), all of which are covered by the undertaking. Dr. Kang also indirectly holds 5,000,000 shares (about 6.35%) through Xiamen Tairuihe Investment Partnership (Limited Partnership), an employee shareholding platform whose limited partnership interests are held by employees of the Group and of which Dr. Kang is the sole general partner and executive partner; those shares fall outside the undertaking.

The Board believes the undertaking reflects the controlling shareholders' confidence in the Company's long-term prospects and their commitment to align interests with the Company and all shareholders. Haixi Pharma is a biopharmaceutical company focused on the R&D and commercialisation of innovative drugs covering oncology, ophthalmology and other major diseases, and listed on the Main Board of the Stock Exchange of Hong Kong in October 2025. Shareholders and potential investors are advised to exercise caution when dealing in the shares.